Investment Research & Advisory Group’s GSK GSK Stock Holding History

Investment Research & Advisory Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-480	Closed	-$16.9K	–	203
2022 Q4	$16.9K	Hold	480	–	–	0.01%	120
2022 Q3	$14K	Sell	480 -427	-47%	-$16.2K	0.01%	122
2022 Q2	$49K	Buy	907 +427	+89%	+$23.6K	0.04%	95
2022 Q1	$26K	Hold	480	–	–	0.02%	119
2021 Q4	$26K	Hold	480	–	–	0.02%	122
2021 Q3	$23K	Hold	480	–	–	0.02%	114
2021 Q2	$24K	Hold	480	–	–	0.02%	122
2021 Q1	$21K	Hold	480	–	–	0.02%	116
2020 Q4	$22K	Sell	480 -211	-31%	-$9.69K	0.02%	114
2020 Q3	$33K	Hold	691	–	–	0.03%	105
2020 Q2	$35K	Hold	691	–	–	0.03%	102
2020 Q1	$33K	Buy	691 +480	+227%	+$25.6K	0.03%	97
2019 Q4	$12K	Buy	+211	New	+$11.7K	0.01%	148

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Investment Research & Advisory Group's GSK Position: Q1 2023 in Review

Investment Research & Advisory Group sold out of GSK (GSK) in Q1 2023, closing a stake of 480 shares — an estimated $16.9K sold.

Investment Research & Advisory Group first reported a position in GSK in Q4 2019 and held it in 13 quarters. The position peaked at $49K in Q2 2022. 809 funds tracked by Wall St. Rank hold GSK as of Q1 2023.

Investment Research & Advisory Group reported no remaining GSK position as of Q1 2023 after selling out during the quarter.
Investment Research & Advisory Group sold 480 GSK shares in Q1 2023, an estimated $16.9K.
Investment Research & Advisory Group first reported a position in GSK in Q4 2019 and held it in 13 quarters.
Investment Research & Advisory Group's GSK position peaked at $49K in Q2 2022.
809 funds tracked by Wall St. Rank held GSK as of Q1 2023.

Based on Investment Research & Advisory Group's 13F filing for Q1 2023, filed 19 Apr 2023.